NASDAQ:SNPX Synaptogenix (SNPX) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free SNPX Stock Alerts $4.53 +0.12 (+2.72%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$4.34▼$4.5450-Day Range$4.33▼$6.6452-Week Range$3.53▼$47.00Volume6,926 shsAverage Volume74,924 shsMarket Capitalization$4.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Synaptogenix alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Synaptogenix Stock (NASDAQ:SNPX)Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.Read More SNPX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNPX Stock News HeadlinesApril 24, 2024 | finanznachrichten.deSynaptogenix, Inc.: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingApril 24, 2024 | prnewswire.comSynaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingApril 28, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 5, 2024 | uk.investing.comSynaptogenix announces reverse stock split to regain Nasdaq complianceApril 4, 2024 | msn.comWhat's Going On With Synaptogenix (SNPX) Stock?April 3, 2024 | finance.yahoo.comSynaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingFebruary 22, 2024 | msn.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 1.18%December 19, 2023 | finance.yahoo.comSynaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersApril 28, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.December 6, 2023 | finance.yahoo.comSynaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sNovember 2, 2023 | finance.yahoo.comSynaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of TechnologySeptember 26, 2023 | finance.yahoo.comSynaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's DiseaseSeptember 7, 2023 | finance.yahoo.comBryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent StudyJuly 19, 2023 | prnewswire.comSynaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple SclerosisJuly 14, 2023 | benzinga.comShort Volatility Alert: Synaptogenix IncJuly 13, 2023 | benzinga.comSynaptogenix Shares Halted On Circuit Breaker To The Upside, Stock Now Up 59.1%July 13, 2023 | marketwatch.comSynaptogenix Shares Rise 48% After Alzheimer's Drug Abstract Accepted at ConferenceJuly 13, 2023 | finance.yahoo.comSynaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of NeuroscienceJune 24, 2023 | finance.yahoo.comSNPX - Synaptogenix, Inc.March 7, 2023 | finance.yahoo.comSynaptogenix Provides Corporate Update and Outlines Potential Business OpportunitiesFebruary 27, 2023 | reuters.comSNPX.ODecember 20, 2022 | msn.comPeering Into Synaptogenix's Recent Short InterestDecember 16, 2022 | seekingalpha.comSynaptogenix crashes 69% as Phase 2 trial for Alzheimer’s candidate failsDecember 16, 2022 | finance.yahoo.comSynaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's DiseaseDecember 9, 2022 | seekingalpha.comSynaptogenix: Bryostatin For Alzheimer's, As Binary As Can BeNovember 18, 2022 | seekingalpha.comSynaptogenix announces $15M private placement with existing investorsNovember 18, 2022 | finance.yahoo.comSynaptogenix Announces $15 Million Private Placement with Existing InvestorsSee More Headlines Receive SNPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synaptogenix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SNPX CUSIPN/A CIK1571934 Webwww.synaptogen.com Phone973-242-0005FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($26.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-22.50% Return on Assets-18.10% Debt Debt-to-Equity RatioN/A Current Ratio7.14 Quick Ratio7.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$25.27 per share Price / Book0.18Miscellaneous Outstanding Shares1,090,000Free Float1,038,000Market Cap$4.94 million OptionableNot Optionable Beta1.33 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Alan J. Tuchman M.D. (Age 77)MBA(FAAN), CEO & Director Comp: $303.35kDr. Daniel L. Alkon M.D. (Age 82)President, Chief Scientific Officer & Director Comp: $375kMr. Robert Weinstein (Age 64)CFO, Executive VP, Treasurer & Secretary Comp: $568.92kKey CompetitorsAlzamend NeuroNASDAQ:ALZNBright Minds BiosciencesNASDAQ:DRUGGT BiopharmaNASDAQ:GTBPOragenicsNYSE:OGENKintara TherapeuticsNASDAQ:KTRAView All Competitors SNPX Stock Analysis - Frequently Asked Questions How have SNPX shares performed in 2024? Synaptogenix's stock was trading at $6.7975 at the beginning of the year. Since then, SNPX shares have decreased by 33.4% and is now trading at $4.53. View the best growth stocks for 2024 here. Are investors shorting Synaptogenix? Synaptogenix saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 33,700 shares, an increase of 183.2% from the March 31st total of 11,900 shares. Based on an average daily trading volume, of 48,500 shares, the short-interest ratio is presently 0.7 days. Approximately 3.2% of the company's shares are short sold. View Synaptogenix's Short Interest. When is Synaptogenix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SNPX earnings forecast. When did Synaptogenix's stock split? Shares of Synaptogenix reverse split on Friday, April 5th 2024. The 1-25 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Synaptogenix? Shares of SNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SNPX) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHas Jeff Bezos Found the Next Nvidia?InvestorPlaceThe only accurate crypto trading system I know …Weiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
